Table 1 Baseline characteristics of study population
|  | SGLT-2i group (n = 128) | Non-SGLT-2i group (n = 104) | P value |
|---|---|---|---|
Age, years | 64 (56,70) | 67 (57,71) | 0.325 |
Male (%) | 96 (75.0%) | 79 (76.7%) | 0.765 |
BMI, kg/m2 | 24.92 \(\pm 3.46\) | 24.51 \(\pm 3.40\) | 0.384 |
ACS (%) | Â | Â | 0.174 |
 Unstable angina | 44 (34.4%) | 27 (26.0%) |  |
 NSTEMI | 33 (25.8%) | 23 (22.1%) |  |
 STEMI | 51 (39.8%) | 54 (51.9%) |  |
Smoking (%) | 70 (54.7%) | 61 (58.7%) | 0.545 |
Old stroke (%) | 9 (7.0%) | 6 (5.8%) | 0.697 |
Hypertension (%) | 89 (69.5%) | 55 (52.9%) | 0.009 |
CAD (%) | 17 (13.3%) | 19 (18.3%) | 0.297 |
Congestive heart failure (%) | 4 (3.1%) | 0 (0.00%) | 0.130 |
Duration of T2DM, years | 1.0 (0,10) | 3.5 (0,10) | 0.255 |
High Risk of in-hospital death (%) | 39 (30.5%) | 39 (37.5%) | 0.260 |
Gensini score | 48.0 (24.0,80.0) | 47.5 (22.8,82.0) | 0.824 |
Coronary stenting (%) | 100 (78.1%) | 84 (80.8%) | 0.621 |
Drugs | |||
 Antiplatelet therapy (%) | 128 (100%) | 104 (100%) |  |
 β-Blocker (%) | 97 (75.8%) | 80 (76.9%) | 0.839 |
 Lipid-lowering therapy (%) | 128 (100%) | 104 (100%) |  |
 ACEi/ARB/ARNi (%) | 98 (76.6%) | 67 (67.3%) | 0.117 |
 CCBs (%) | 21 (16.4%) | 10 (9.6%) | 0.131 |
 Diuretics (%) | 25 (19.5%) | 24 (23.1%) | 0.511 |
 Insulin (%) | 31 (24.2%) | 27 (26.0%) | 0.760 |
 Sulfonylurea (%) | 15 (11.7%) | 15 (14.4%) | 0.542 |
 GLP-1 receptor agonist (%) | 15 (11.7%) | 9 (8.7%) | 0.446 |
 DPP-IV Inhibitors (%) | 3 (2.3%) | 3 (2.9%) | 0.796 |
 Metformin (%) | 71 (55.5%) | 60 (57.7%) | 0.734 |
 Empagliflozin (%) | 81 (63.3%) | 0 (0%) |  |
 Dapagliflozin (%) | 47 (36.7%) | 0 (0%) |  |
Biochemical indicators | |||
 HbA1c | 7.60 (6.30,8.90) | 7.40 (6.63,8.38) | 0.635 |
 Scr, mmol/L | 74 (62,89) | 71 (59,84) | 0.169 |
 UA, μmol/L | 335 (272,409) | 331 (277,390) | 0.593 |
 TC, mmol/L | 4.36 (3.66,5.04) | 4.01 (3.40,4.94) | 0.195 |
 HDL, mmol/L | 0.96 (0.86,1.12) | 0.95 (0.81,1.13) | 0.346 |
 LDL, mmol/L | 2.54 (1.99,3.19) | 2.39 (1.76,3.14) | 0.219 |
 LP(α), mmol/L | 102 (57,290) | 133 (46,391) | 0.835 |
 hs-CRP, mg/dL | 3.52 (1.68,10.94) | 4.53 (1.44,12.45) | 0.846 |
Echocardiographic | |||
 LVEF (%) | 59 (48,63) | 58 (49,63) | 0.516 |
 LAD (mm) | 33 (31,36) | 32 (30,35) | 0.022 |
 LVIDd (mm) | 48 (45,51) | 48 (44,48) | 0.969 |
 IVSd (mm) | 10 (10,11) | 10 (10.11) | 0.537 |
 LVPWd (mm) | 10 (10,11) | 10 (10,11) | 0.389 |